

Modeling of DTPA decorporation therapy

Still puzzling after all these years

Institute for nuclear waste disposal (INE)

B. Breustedt , KIT, Germany
E. Blanchardon, IRSN, France
P. Berard, CEA, France
P. Fritsch, CEA, France
O. Gremy, CEA, France
A. Giussani, BfS, Germany
M.A. Lopez, CIEMAT, Spain

IRSIN INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE

œ

Ciemat

Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas

Bundesamt für Strahlenschutz



energie atomique · energies alternatives






Dose assessment after Incorporation of Radionuclides is based on

Measurements

- Urinary or fecal analysis
- Whole/partial body counting (where possible)

Modeling

- Biokinetic behaviour of radionuclide
- Distribution of dose deposition






- Studies on Biokinetics of Plutonium and other Actinides
 - First human injection studies
 - Langham et al.






- Studies on Biokinetics of Plutonium and other Actinides
 - First human injection studies
 - Langham et al.
 - Animal studies
 - Beagles, Rats, Mice, ...
 (Univ. Utah, PNNL, LRRI, ...)





- Studies on Biokinetics of Plutonium and other Actinides
 - First human injection studies
 - Langham et al.
 - Animal studies
 - Beagles, Rats, Mice, ... (Univ. Utah, PNNL, LRRI, ...)
 - Latest Studies with human volunteers
 - Talbot et al., Newton et al.



Langham et al.

DTPA – still puzzling after all these years

Studies on Biokinetics of Plutonium and other Actinides

- Animal studies
 - Beagles, Rats, Mice, ... (Univ. Utah, PNNL, LRRI, ...)

First human injection studies


- Latest Studies with human volunteers
 - Talbot et al., Newton et al.
- Mathematical models of Pu and Actinide biokinetics
 - ICRP models (ICRP Publications 48, 67)
 - Latest model: Leggett et al. (2005)



1940s

1980s

1990s




1970s

1960s


mask the metal ion from it's "standard" processess

- Rapid excretion of masked metal-ion
- If plutonium/actinide is removed from body it cannot deliver a dose inside
 - \rightarrow averted dose

Decorporation therapy: Idea










Dr. Bastian Breustedt - DTPA, still puzzling after all these years 30.07.2015

Institute for nuclear waste disposal

DTPA – still puzzling after all these years

- Decorporation therapy: Idea
 - mask the metal ion from it's "standard" processess
 - Rapid excretion of masked metal-ion
 - If plutonium/actinide is removed from body it cannot deliver a dose inside
 - \rightarrow averted dose


- Development of several chelating agents
 - DTPA available since 1960s




1960s




1940s




- Biokinetics of DTPA
 - Human Study: Stather et al. 1983
 - Reinterpretation: CONRAD Project 2008





Taken from: Lopez M.A. et al., Final Report of CONRAD Work Package 5, CIEMAT-Report, Madrid

- Models of DTPA-decorporation therapy
 - "Wait and see" Approach
 - Ignore data from first (100) days after therapy
 - Empirical Approach
 - Description of urinary excretion by mathematical function
 - Add terms describing (independent) additional excretion of Pu-DTPA






1970s

1970s

2000s

- Models of DTPA-decorporation therapy
 - Stop and go" approach
 - Stop undisturbed model at time of therapy
 - Shift part of compartmental contens to urinary excretion
 - Continue calculation


10








- Models of DTPA-decorporation therapy
 - Modification of existing compartmental models
 - Mostly case specific modeling
 - Additional compartments representing DTPA/Pu-DTPA
 - Multiplication factors for transfer rates




Taken from: James, AC et al. , Radiation Protection Dosimetry, 127(1-4), 449-455, 2007.






Models of DTPA-decorporation therapy

- Expilict consideration of in-vivo chelation process
 - Coupling of Pu-model and DTPA-model




2nd order kinetics

Taken from: Lopez M.A. et al., Final Report of CONRAD Work Package 5, CIEMAT-Report, Madrid







- Some open questions about DTPA decorporation
 - Where does the chelation take place?
 - Distribution volume of DTPA?
 - Which parts of the models are affected?
 - In-vivo chemistry of chelation?
 - Competitors for reactands?
 - Bio-ligands (e.g. Transferrin, Citrate)
 - Metal-ions (e.g. Zn-DTPA vs. Ca-DTPA)
 - Transfer of results from in-vitro studies \rightarrow in-vivo
 - Influence of environment at location of chelation







DTPA – keep puzzling after all these years



